Simile’s $200M Series B pushes synthetic user market to $2B valuation
Simile closed a $200 million Series B at a $2 billion post‑money valuation, just five months after its $100 million Series A. The funding, led by Greenoaks with Index Ventures and CVS Health Ventures, backs its synthetic‑user platform for marketing and product research, underscoring growing investor confidence in AI‑driven consumer simulations.